All Blogs

Aug 19, 2016

Zymeworks licenses new drug discovery platform from Innovative Targeting Solutions Zymeworks, a biotech company working on bispecific antibodies, has signed a licensing deal with Innovative Targeting Solutions (ITS) for HuTARG, which works as a protein engineering platform, and is the first fully mammalian tech that...

Aug 18, 2016

Branded product portfolio of Shionogi acquired by Lupin Pharma giant Lupin entered into a strategic agreement when its Japanese subsidiary Kyowa Pharmaceutical Industry Co. purchased the product portfolio of Japan’s Shionogi & Co., Ltd. The agreement results in acquisition of 21 products long-listed, and the dea...

Aug 17, 2016

Some collaborations change the face of treatment scenario, and this collaboration is one example of that. An immunologist collaborated with an oncologist to help fight the immunologist’s stepmother fight cancer, and turned the face of transformative therapy. The discovery is of a new class of drugs that help in bypa...

Aug 16, 2016

To download the pdf version of the Newsletter: Click the following DelveInsight Newsletter

Aug 11, 2016

Spinal Muscular Atrophy (SMA) is a rare genetic and neuromuscular condition which affects mainly children. It has several distinct types such as type 1 (Werdnig-Hoffmann disease), type 2 (Dubowitz disease), type 3 (Kugelberg-Welander disease) and type 4 (Adult onset). SMN1 (Survival Motor Neuron 1) is the primary ge...

Aug 04, 2016

NZ’s PHARMAC to fund six new treatments New Zealand’s Pharmac received $124 million as part of funding boost by the NZ Government in 2016 Budget. The funding would be used for the treatment of six new treatments. Opdivo (nivolumab) for advanced melanoma, rituximab for nephrotic syndrome in children, and Har...

Aug 03, 2016

Cancer has gripped the world in its clutches, and the grip hasn’t loosened for the past 3 decades. Research into cancer prognosis and treatment has many hurdles, and these hurdles keep on increasing with increasing insight to the disease itself. In terms of glioblastoma as well, the researchers have not had much suc...

Aug 02, 2016

Juno Therapeutics recently acquired Redox Therapies and it’s vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist. The upfront consideration for the Redox Therapies acquisition was $10 million in cash. UK-based Cell Medica expands its T cell immunotherapy program with the acquisition of privatel...

Aug 01, 2016

For over 100 years, immunotherapy has played a significant role in the treatment of cancer. Immune stimulatory agents such as Toll-like receptor (TLR) agonists, adoptive T cell and natural killer (NK) cell therapies, cytokine-based therapies etc. have gained approval for treatment of various indications. In 1980s, r...

May 31, 2016

The Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020. DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Antico...